Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro-DexPDEX -0.51%69 EV-to-EBIT is 13.07 as of Aug. 20, 2026, which is 12% above its 10-year median of 11.69. GuruFocus rates PDEX with a GF Score™ of 69/100 and a GF Value™ of $40.81 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Pro-Dex ranks better than 68.22% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pro-Dex's Enterprise Value is $220.40 Mil.
Pro-Dex's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $16.86 Mil. Therefore, Pro-Dex's EV-to-EBIT for today is 13.07.
The historical rank and industry rank for Pro-Dex's EV-to-EBIT or its related term are showing as below:
PDEX'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.73 Med: 11.69 Max: 31.84
Current: 13.07
During the past 13 years, the highest EV-to-EBIT of Pro-Dex was 31.84. The lowest was 5.73. And the median was 11.69.
PDEX's EV-to-EBIT is ranked better than 68.22% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.665
vs PDEX: 13.07
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pro-Dex's Enterprise Value for the quarter that ended in Mar. 2026 was $165.39 Mil.
Pro-Dex's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro-Dex EV-to-EBIT Related Terms
Pro-Dex EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pro-Dex's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Pro-Dex's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro-Dex EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pro-Dex's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pro-Dex's EV-to-EBIT falls into.
Pro-Dex's current Enterprise Value is $220.40 Mil.
Pro-Dex's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro-Dex (PDEX) has a EV-to-EBIT of 13.07 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pro-Dex and its competitors. This is 12% above median its historical median of 11.69. Over the past decade, Pro-Dex's EV-to-EBIT has ranged from 5.73 to 31.84. According to the industry distribution chart, Pro-Dex ranks #150 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 31.8%.
Is Pro-Dex's EV-to-EBIT too high?
Pro-Dex's current EV-to-EBIT of 13.07 is 12% above median its 10-year median of 11.69. Over the past 10 years, this metric has ranged from a low of 5.73 to a high of 31.84. The Medical Devices & Instruments industry median EV-to-EBIT is 19.67. Pro-Dex's value of 13.07 is 33.5% below this industry median. Based on the distribution chart, Pro-Dex ranks #150 out of 472 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pro-Dex has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pro-Dex's EV-to-EBIT compare to KRMD and EMBC?
According to the Medical Devices & Instruments industry distribution chart, Pro-Dex ranks #150 out of 472 companies for EV-to-EBIT. This puts Pro-Dex in the upper half of its industry. The industry median EV-to-EBIT is 19.67. Pro-Dex's value of 13.07 is 33.5% below this benchmark. Historically, Pro-Dex's own EV-to-EBIT has ranged from 5.73 to 31.84 over the past decade. While the company's 10-year median is 11.69 vs. the industry median of 19.67, Pro-Dex has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.67, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro-Dex's current EV-to-EBIT of 13.07 is 33.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pro-Dex and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro-Dex's current EV-to-EBIT is 13.07, which is 12% above median its own 10-year median of 11.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro-Dex stock overvalued right now?
Based on GuruFocus' analysis, Pro-Dex (PDEX) is currently considered Significantly Overvalued. The stock's GF Value™ is $40.81, compared to a current price of $66.42 — trading 62.7% above its estimated fair value. The current EV-to-EBIT is 13.07, which is 12% above median its 10-year median of 11.69 and 33.5% below the Medical Devices & Instruments industry median of 19.67. Pro-Dex's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pro-Dex (PDEX), the current EV-to-EBIT is 13.07 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro-Dex (PDEX) Overvalued in 2026?
Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued.
The current stock price of $66.42 is trading 62.7% above its estimated GF Value™ of $40.81.
GuruFocus considers Pro-Dex to be Significantly Overvalued.
Key valuation signals for PDEX:
EV-to-EBIT: 13.07 (12% above median its 10-year median of 11.69)
GF Value™: $40.81 vs. price of $66.42 (62.7% above fair value)
Industry Position: 33.5% below the Medical Devices & Instruments median (#150 of 472)
No single metric tells the full story. See the PDEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
69GF Score
Get the complete analysis for PDEX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDEX has been successfully added to your 
